CYANAGEN SRL

Their core work

CYANAGEN is a Bologna-based Italian SME specializing in the development and production of cyanine-based near-infrared (NIR) fluorescent dyes and cell-tracking nanoparticles used in biomedical research and preclinical imaging. Their core value to research consortia is supplying specialized optical reagents that make it possible to track stem cells, nanoparticles, and biological structures non-invasively in living tissue. In the RenalToolBox project they contributed NIR imaging tools and mathematical analysis capabilities to support assessment of cell-based regenerative therapies for kidney disease. Their commercial focus is reagent supply and imaging chemistry rather than clinical development or data analysis.

What they specialise in

How they've shifted over time

CYANAGEN's two projects span 2016 to 2023, and their trajectory shows a shift from diagnostic biomarker applications toward regenerative medicine tracking tools. The BIOFOSTE project (2016) was about validating a clinical biomarker panel for osteoarthritis — a diagnostics-oriented context where their dye chemistry would serve detection purposes. By RenalToolBox (2018–2023), the focus had moved to stem cell therapy assessment, NIR cell tracking, and mathematical image analysis tools — a more research-intensive, therapy-monitoring application. The direction is clearly toward providing enabling imaging tools for next-generation cell and gene therapies rather than conventional diagnostics.

CYANAGEN is positioning itself as a reagent and imaging chemistry supplier for cell therapy evaluation — a growing niche as mesenchymal stem cell and regenerative medicine trials scale up in Europe.

How they like to work

CYANAGEN has participated in EU projects exclusively as a partner, never as coordinator — a pattern typical of specialist reagent suppliers who bring a defined product or technology rather than scientific leadership. They have worked with 14 unique partners across 7 countries in just two projects, suggesting they join mid-to-large consortia where their niche chemistry expertise fills a specific gap. Working with them likely means a well-scoped, product-supply type of engagement rather than joint scientific leadership.

CYANAGEN has built connections with 14 consortium partners across 7 countries in only two projects, indicating they join sizeable international consortia. Their network is European in scope with no dominant geographic cluster apparent from the data.

What sets them apart

CYANAGEN occupies a narrow but valuable niche: commercial-grade NIR fluorescent dyes and cell-tracking nanoparticles purpose-built for biomedical research, produced by a small Italian SME with direct EU project validation experience. Unlike academic labs that develop imaging probes as research outputs, CYANAGEN's role as a private company suggests these are manufacturable, reproducible products — a practical advantage for consortia that need validated reagents they can actually procure. For a consortium building a cell therapy or imaging platform, they bring both the chemistry and the regulatory-adjacent experience from preclinical safety and efficacy work.

Highlights from their portfolio

• RenalToolBox
  The largest and most technically specific of their projects, spanning five years (2018–2023) with EUR 261,500 EC funding, covering stem cell tracking, NIR dyes, multimodal imaging, and mathematical image analysis for kidney regenerative medicine — the clearest window into CYANAGEN's actual technical contributions.
• BIOFOSTE
  Their earliest EU project (2016), focused on clinical biomarker validation for osteoarthritis, shows CYANAGEN's reagent capabilities extend into clinical diagnostics beyond regenerative medicine.